XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net loss $ (1,597) $ (7,850)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation 1,083 1,122
Amortization of intangible assets 4,138 4,492
Amortization of deferred financing costs 210 210
Stock-based compensation expense 3,618 3,401
Deferred income taxes and other 92 (160)
Unrealized loss on equity securities - Note 14 373 0
Convertible Preferred Stock received in Biostage settlement - Note 14 0 (3,900)
Gain on sale of product line (403) 0
Changes in operating assets and liabilities:    
Accounts receivable 1,751 6,060
Inventories 173 (329)
Other assets (50) (811)
Accounts payable and other current liabilities 695 (2,379)
Deferred revenue, change 635 (551)
Other liabilities (993) (832)
Net cash provided by (used in) operating activities 9,725 (1,527)
Cash flows from investing activities:    
Additions to property, plant and equipment (958) (1,355)
Acquisition of intangible assets (292) 0
Proceeds from sale of product line 512 0
Net cash used in investing activities (738) (1,355)
Cash flows from financing activities:    
Borrowing from revolving line of credit 3,500 7,800
Repayment of revolving line of credit (8,450) (4,650)
Repayment of term debt (3,341) (2,436)
Proceeds from exercise of stock options and employee stock purchase plan 724 346
Taxes paid related to net share settlement of equity awards (451) (1,167)
Net cash used in financing activities (8,018) (107)
Effect of exchange rate changes on cash (137) 312
Increase (decrease) in cash and cash equivalents 832 (2,677)
Cash and cash equivalents at beginning of period 4,508 7,821
Cash and cash equivalents at end of period 5,340 5,144
Supplemental disclosures of cash flow information:    
Cash paid for interest 3,006 1,529
Cash paid for income taxes, net of refunds $ 168 $ 493